Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.
Plasma cell microaggregates detected by CD138 immunohistology were demonstrated in 22% of patients achieving morphologic remission 3 months after high-dose therapy for myeloma. Microaggregates were predictive of earlier disease progression, indicating that immunohistology may represent a useful tool in the assessment of minimal disease in patients after high-dose therapy for myeloma.
Wei
Andrew
A
Westerman
David
D
Feleppa
Frank
F
Trivett
Melanie
M
Juneja
Surender
S
D001854:Bone Marrow Cells / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D018365:Neoplasm, Residual / Q000473:pathology*; D010950:Plasma Cells / Q000473:pathology; D011237:Predictive Value of Tests; D012008:Recurrence; D033581:Stem Cell Transplantation